Independent
Tenure on this board
4.4 yrs
Also a director at
3M Co (MMM)
Meeting calendar
BDX · Annual meeting · Tuesday, January 27, 2026
Becton Dickinson & Co
13 nominees.
BD's 2026 Annual Meeting will consider four proposals: 1) Election of directors (thirteen nominees) for a one-year term; 2) Ratification of the selection of the independent registered public accounting firm (E&Y) for fiscal year 2026; 3) Advisory vote to approve named executive officer compensation; 4) Approval of an amendment to the 2004 BD Employee and Director Equity-Based Compensation Plan to increase shares for awards.
Market cap
$42.7B
1Y TSR
-14.0%
Board grade
C
Record date
Dec 8, 2025
Filing
DEF 14A
Meeting concluded · Jan 27, 2026
Follow how the vote landed and what changed on Becton Dickinson & Co’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot
Proposal list not yet available for this filing.
Director elections
Nominees on the ballot13
Independent
Tenure on this board
4.7 yrs
Independent
Tenure on this board
9.8 yrs
Also a director at
Maravai Lifesciences Holdings Inc (MRVI)
Independent
Tenure on this board
19.2 yrs
Also a director at
Seres Therapeutics Inc (MCRB)Waters Corp (WAT)
Independent
Tenure on this board
1.3 yrs
Also a director at
Phillips 66 (PSX)
Independent
Tenure on this board
7.9 yrs
Also a director at
Halozyme Therapeutics Inc (HALO)Qualcomm Inc (QCOM)
Independent
Tenure on this board
0.6 yrs
Also a director at
Insulet Corp (PODD)Eikon Therapeutics Inc (EIKN)
Independent
Tenure on this board
16.0 yrs
Not independent
Tenure on this board
4.5 yrs
Independent
Tenure on this board
6.8 yrs
Also a director at
Quest Diagnostics Inc (DGX)
Independent
Tenure on this board
24.5 yrs
Also a director at
Lowes Companies Inc (LOW)Equitable Holdings Inc (EQH)Dollar Tree Inc (DLTR)
Independent
Tenure on this board
3.0 yrs
Also a director at
Structure Therapeutics Inc (GPCR)
Independent
Tenure on this board
0.6 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.7% | 18,490,610 | $2.9B |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.6% | 15,317,242 | $2.4B |
| 3 | STATE STREET CORP | 5.0% | 13,822,808 | $2.2B |
| 4 | First Eagle Investment Management, LLC | 4.2% | 11,703,685 | $1.8B |
| 5 | T. Rowe Price Investment Management, Inc. | 3.5% | 9,685,271 | $1.5B |
| 6 | BlackRock, Inc. | 3.1% | 8,642,293 | $1.4B |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 2.3% | 6,424,155 | $1.0B |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 6,191,386 | $970M |
| 9 | BlackRock, Inc. | 2.2% | 6,155,370 | $968M |
| 10 | Invesco Ltd. | 1.5% | 4,211,338 | $662M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Becton Dickinson & Co’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Steris PLCSTE
Annual meeting·Jul 31, 2026·$20.6B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.0B
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.5B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Reference
Frequently asked questions
- When is the Becton Dickinson & Co 2026 annual meeting?
- Becton Dickinson & Co (BDX) holds its 2026 annual shareholder meeting on Tuesday, January 27, 2026.
- What is the record date for the Becton Dickinson & Co 2026 meeting?
- The record date for the Becton Dickinson & Co 2026 meeting is Monday, December 8, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Becton Dickinson & Co's 2026 meeting?
- The board is presenting 13 director nominees at the Becton Dickinson & Co 2026 meeting, listed with their independence status and background.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.